<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080391</url>
  </required_header>
  <id_info>
    <org_study_id>PX-171-009</org_study_id>
    <nct_id>NCT01080391</nct_id>
  </id_info>
  <brief_title>Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma</brief_title>
  <official_title>A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare progression-free survival in subjects with relapsed multiple myeloma who are
      receiving CRd vs subjects receiving Rd in a randomized multicenter setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, randomized, open-label, multicenter study comparing two treatment regimens
      for subjects with relapsed multiple myeloma. Eligible subjects will be randomized in a 1:1
      ratio to receive either the control Rd or CRd. Randomization will be stratified by β2
      microglobulin levels (&lt; vs ≥ 2.5 mg/L), prior bortezomib (no vs yes), and prior lenalidomide
      (no vs yes). Subjects will receive the treatment determined by randomization in 28-day cycles
      until disease progression or unacceptable toxicity (whichever occurs first). The primary
      endpoint of this Phase 3 study is progression-free survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 6, 2010</start_date>
  <completion_date type="Actual">December 5, 2017</completion_date>
  <primary_completion_date type="Actual">June 16, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.</time_frame>
    <description>Kaplan-Meier estimate of median time from randomization to progressive disease (PD) or all-cause death. PD was assessed using International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). 1 or more conditions were required to meet PD: 2 consecutive rising serum or urine M-protein from central lab; documented new bone lesion(s) or soft tissue plasmacytoma(s) or increased size of existing bone lesion(s) or plasmacytoma(s); or confirmed hypercalcemia due solely to plasma cell proliferative disorder (local lab greater than 11.5 mg/dL on 2 separate occasions). Censoring conditions (censoring dates) were: no post-baseline disease assessment (DA) (randomization date); started non-protocol systemic anticancer treatment before PD or death (last DA date before such treatment); died or had PD after more than 1 missed DA (last DA date without PD before the first missed visit); or were alive and without documentation of PD, including lost to follow-up without PD (last DA date).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization through the data cutoff date of 16 June 2014. Median follow up time was approximiately 32 months.</time_frame>
    <description>Time elapsed between the randomization date and the date of death. Participants who were still alive were censored at the date when the subject was last known to be alive or the data cutoff date, whichever occurs earlier. The median and all but one of the 95% confidence limits were not estimable. Instead, the number of participants who died or were censored are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response</measure>
    <time_frame>From randomization through the data cutoff date of 16 June 2014.Median follow-up time was approximately 31 months.</time_frame>
    <description>Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response based on the Independent Review Committee (IRC) assessed response outcome. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control</measure>
    <time_frame>From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.</time_frame>
    <description>Number of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks according to International Myeloma Working Group - Uniform Response Criteria (IMWG-URC) (MR was determined using European Group for Blood and Marrow Transplantation criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 42 months.</time_frame>
    <description>Duration of response (DOR) was calculated for subjects who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented Progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Disease Control</measure>
    <time_frame>From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 46 months.</time_frame>
    <description>Duration of disease control (DDC) was calculated for participants who achieved disease control.DDC was defined as the time in months from randomization to the earlier of documented Progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ-C30 Global Health Status/Quality of Life Scores</measure>
    <time_frame>Day 1 of Cycles 3, 6, 12, 18</time_frame>
    <description>European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Core Module QLQ-C30 (QLQ-C30 GHS/QoL) is a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life. The minimal important difference for between group differences is 5 points.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">792</enrollment>
  <condition>Relapsed Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide and Dexamethasone (Rd)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on Days 1 to 21 and Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m2 was administered intravenously (IV) on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 on Days 8, 9, 15, and 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 through Cycle 12 and then from Cycle 13 through Cycle 18, 27 mg/m2 on Days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on Days 1 to 21 from Cycle 1 through Cycle 18 and from Cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22 from Cycle 1 through Cycle 18 and from Cycle 19 and higher.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg PO or IV on Days 1, 8, 15, 22</description>
    <arm_group_label>Lenalidomide and Dexamethasone (Rd)</arm_group_label>
    <arm_group_label>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>25 mg PO on Days 1-21</description>
    <arm_group_label>Lenalidomide and Dexamethasone (Rd)</arm_group_label>
    <arm_group_label>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>20 mg/m2, 27 mg/m2</description>
    <arm_group_label>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</arm_group_label>
    <other_name>PR-171</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptomatic multiple myeloma

          2. Measurable disease, as defined by one or more of the following (assessed within 21
             days prior to randomization):

               -  Serum M-protein ≥ 0.5 g/dL

               -  Urine Bence-Jones protein ≥ 200 mg/24 hours

               -  For IgA patients whose disease can only be reliably measured by serum
                  quantitative immunoglobulin (qIgA) ≥ 750 mg/dL (0.75 g/dL)

          3. Prior treatment with at least one, but no more than three, regimens for multiple
             myeloma

          4. Documented relapse or progressive disease on or after any regimen

          5. Achieved a response to at least one prior regimen

          6. Age ≥ 18 years

          7. Life expectancy ≥ 3 months

          8. Eastern Cooperative Oncology Group performance status 0-2

          9. Adequate hepatic function, with serum ALT ≤ 3.5 times the upper limit of normal and
             serum direct bilirubin ≤ 2 mg/dL (34 µmol/L) within 21 days prior to randomization

         10. Absolute neutrophil count ≥ 1.0 × 10^9/L within 21 days prior to randomization

         11. Hemoglobin ≥ 8 g/dL (80 g/L) within 21 days prior to randomization

         12. Platelet count ≥ 50 × 10^9/L (≥ 30 × 10^9/L if myeloma involvement in the bone marrow
             is &gt; 50%) within 21 days prior to randomization

         13. Creatinine clearance (CrCl) ≥ 50 mL/minute within 21 days prior to randomization

         14. Written informed consent in accordance with federal, local, and institutional
             guidelines

         15. Females of childbearing potential must agree to ongoing pregnancy testing and to
             practice contraception

         16. Male subjects must agree to practice contraception

        Exclusion Criteria:

          1. If previously treated with bortezomib (alone or in combination), progression during
             treatment

          2. If previously treated with a lenalidomide and dexamethasone (len/dex) combination:

               -  Progression during the first 3 months of initiating treatment

               -  Any progression during treatment if the len/dex combination was the subject's
                  most recent line of therapy

          3. Discontinuation of previous lenalidomide or dexamethasone due to intolerance; subjects
             intolerant to bortezomib are not excluded

          4. Prior carfilzomib treatment

          5. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
             skin changes)

          6. Waldenström's macroglobulinemia or IgM myeloma

          7. Plasma cell leukemia (&gt; 2.0 × 10^9/L circulating plasma cells by standard
             differential)

          8. Chemotherapy or investigational agent within 3 weeks prior to randomization or
             antibody therapy within 6 weeks prior to randomization

          9. Radiotherapy to multiple sites or immunotherapy/antibody therapy within 28 days prior
             to randomization; localized radiotherapy to a single site within 7 days prior to
             randomization

         10. Corticosteroid therapy at a dose equivalent to dexamethasone &gt; 4 mg/day within 21 days
             prior to randomization

         11. Pregnant or lactating females

         12. Major surgery within 21 days prior to randomization

         13. Acute active infection requiring treatment (systemic antibiotics, antivirals, or
             antifungals) within 14 days prior to randomization

         14. Known human immunodeficiency virus infection

         15. Active hepatitis B or C infection

         16. Myocardial infarction within 4 months prior to randomization, NYHA Class III or IV
             heart failure, uncontrolled angina, history of severe coronary artery disease, severe
             uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic
             evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject
             has a pacemaker

         17. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to
             randomization

         18. Other malignancy, including MDS, within the past 3 years with the exception of a)
             adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer;
             b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or
             less with stable prostate-specific antigen levels; or d) cancer considered cured by
             surgical resection or unlikely to impact survival during the duration of the study,
             such as localized transitional cell carcinoma of the bladder or benign tumors of the
             adrenal or pancreas

         19. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to
             randomization

         20. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize
             carfilzomib)

         21. Contraindication to any of the required concomitant drugs or supportive treatments,
             including hypersensitivity to all anticoagulation and antiplatelet options, antiviral
             drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

         22. Ongoing graft-vs-host disease

         23. Subjects with pleural effusions requiring thoracentesis or ascites requiring
             paracentesis within 14 days prior to randomization

         24. Any other clinically significant medical disease or condition that, in the
             Investigator's opinion, may interfere with protocol adherence or a subject's ability
             to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Joseph Medical Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Hospital Yorba Linda dba; St. Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>94503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer and Blood Disease Center</name>
      <address>
        <city>Lecanto</city>
        <state>Florida</state>
        <zip>34461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Michigan - Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Clinical Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology and Hematology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Don &amp; Sybil Harrington Cancer Center</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8565</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert &amp; Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminspital der Stadt Wien, Zentrum fur Onkologie und Hamatologie</name>
      <address>
        <city>Wien</city>
        <zip>1171</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment, &quot;Dr. Georgi Stranski&quot;</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sveti Georgi&quot;</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy Multiprofile Hospital for Active Treatment</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Hematological Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment &quot;Sveta Marina&quot;</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta, Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital, Health Sciences Centre</name>
      <address>
        <city>St John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center, Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis - Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno, Department of Internal Medicine - Hematooncology</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Kralovske Vinohrady - Prague</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital Prague</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Antoine Beclere</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo - Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Mulhouse, Hopital Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Necker - Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institut Universitaire de Toulouse-Oncopole (iUCT)</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux de Brabois</name>
      <address>
        <city>Vandoeuvre-Les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Dusseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftungsklinikum Mittelrhein</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universitat</name>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Munster</name>
      <address>
        <city>Munster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Wurzburg</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Istvan and St. Laszlo Hospital of Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>H-1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Medical and Health Science Center</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar County Teaching Hospital</name>
      <address>
        <city>Gyor</city>
        <zip>H-9032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes County Pandy Kalman Hospital</name>
      <address>
        <city>Gyula</city>
        <zip>H-5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaposi Mor County Teaching Hospital</name>
      <address>
        <city>Kaposvar</city>
        <zip>H-7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pecs</name>
      <address>
        <city>Pecs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Szeged, Albert Szent-Gyorgi Clinical Center</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center, Ein Kerem</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Gailee Hospital - Nahariya</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedallera Niguarda Ca Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedllero Maggiore della Carita</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pisana Ospendale Santa Chiara - Main</name>
      <address>
        <city>Pisa</city>
        <zip>56216</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Eugenio</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Citta della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC, Department of Haematology</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre, Department of Hematologii Transplantologii</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publ. Szp. Wojewodzki w Gorzow Wlkp.</name>
      <address>
        <city>Gorzow Wielkopolski</city>
        <zip>66-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Public Teaching Hospital of Medical University of Silesia in Katowice</name>
      <address>
        <city>Katowice</city>
        <zip>40-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicolaus Copernicus Memorial Provincial Specialist Hospital in Lodz</name>
      <address>
        <city>Lodz</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewwodzki im. dr Ludwika Rydygiera w Suwalkach</name>
      <address>
        <city>Suwalki</city>
        <zip>16-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicolaus Copernicus Municipal Specialist Hospital</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Institute of Oncology</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zamojski Non-Public Hospital</name>
      <address>
        <city>Zamosc</city>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute, &quot;Stefan Berceanu&quot; Center for Hematology and Bone Marrow Transplantation</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coltea Clinical Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>030-171</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bucharest University Emergency Hospital</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Institute of Iasi</name>
      <address>
        <city>Iasi</city>
        <zip>700483</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution Komi Republican Oncological Center</name>
      <address>
        <city>Syktyvkar</city>
        <state>Komi Republic</state>
        <zip>167904</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Republican Clinical Hospital under the Ministry of Healthcare of the Republic of Udmurtia</name>
      <address>
        <city>Izhevsk</city>
        <zip>426039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Scientific Institution: N.N. Blokhin Russian Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Medical Institution Municipal City Clinical Hospital n.a. S.P. Botkin</name>
      <address>
        <city>Moscow</city>
        <zip>125101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution: Hematology Research Center under MoH</name>
      <address>
        <city>Moscow</city>
        <zip>125167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI: Russian Research Institute of Hematology and Blood Transfusion under the Ferderal Agency for M&amp;B</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Higher Educational Institution: St Petersburg State Medical University n.a.I.P Pavlov</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHEI: First St. Petersburg State Medical University N.a.I.P Pavlov under MoH, Clinic of Bone Marrow Transplant</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institute: Federal Almalov Medical Research Centre under Ministry of Healthcare</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia, Clinic of Hematology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy, Clinic of Hematology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis, Clinic of Hematology</name>
      <address>
        <city>Nis</city>
        <zip>18 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Vojvodina, Clinic of Hematology</name>
      <address>
        <city>Novi Sad</city>
        <zip>21 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politeecnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Goteborg</city>
        <zip>SE-41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetsjukhuset i Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Solna, Hematologiskt Centrum</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hampstead</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Georges Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals (City Campus)</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Wolverhampton Hospital NHS Trust</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 OQP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. doi: 10.1182/blood-2016-03-707596. Epub 2016 Jul 20.</citation>
    <PMID>27439911</PMID>
  </reference>
  <reference>
    <citation>Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol. 2016 Nov 10;34(32):3921-3930. doi: 10.1200/JCO.2016.66.9648.</citation>
    <PMID>27601539</PMID>
  </reference>
  <reference>
    <citation>Jakubowiak AJ, Campioni M, Benedict Á, Houisse I, Tichy E, Giannopoulou A, Aggarwal SK, Barber BL, Panjabi S. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016 Nov;19(11):1061-1074. Epub 2016 Jun 16.</citation>
    <PMID>27224006</PMID>
  </reference>
  <reference>
    <citation>Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Ro S, Aggarwal S, Moreau P, Palumbo A. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017 Apr 21;7(4):e554. doi: 10.1038/bcj.2017.31.</citation>
    <PMID>28430175</PMID>
  </reference>
  <reference>
    <citation>Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau P. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017 May;177(3):404-413. doi: 10.1111/bjh.14549. Epub 2017 Feb 17.</citation>
    <PMID>28211560</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2010</study_first_posted>
  <results_first_submitted>June 8, 2015</results_first_submitted>
  <results_first_submitted_qc>June 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2015</results_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 14 July 2010 to 15 Mar 2012. Results are reported as of the data cut-off date of 16 June 2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide and Dexamethasone (Rd)</title>
          <description>Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on Days 1 to 21 and Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22.</description>
        </group>
        <group group_id="P2">
          <title>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</title>
          <description>Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m2 was administered intravenously (IV) on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 on Days 8, 9, 15, and 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 through Cycle 12 and then from Cycle 13 through Cycle 18, 27 mg/m2 on Days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on Days 1 to 21 from Cycle 1 through Cycle 18 and from Cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22 from Cycle 1 through Cycle 18 and from Cycle 19 and higher.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
                <participants group_id="P2" count="396"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="389"/>
                <participants group_id="P2" count="392"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="373">Participants are ongoing as of 16 June 2014 or who have died on study.</participants>
                <participants group_id="P2" count="383">Participants are ongoing as of 16 June 2014 or who have died on study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide and Dexamethasone (Rd)</title>
          <description>Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on Days 1 to 21 and Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22.</description>
        </group>
        <group group_id="B2">
          <title>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</title>
          <description>Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m2 was administered intravenously (IV) on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 on Days 8, 9, 15, and 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 through Cycle 12 and then from Cycle 13 through Cycle 18, 27 mg/m2 on Days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on Days 1 to 21 from Cycle 1 through Cycle 18 and from Cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22 from Cycle 1 through Cycle 18 and from Cycle 19 and higher.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="396"/>
            <count group_id="B2" value="396"/>
            <count group_id="B3" value="792"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" spread="9.04"/>
                    <measurement group_id="B2" value="63.3" spread="9.21"/>
                    <measurement group_id="B3" value="63.9" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="345"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Native Hawaiian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="377"/>
                    <measurement group_id="B2" value="377"/>
                    <measurement group_id="B3" value="754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum β2 Microglobulin</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 2.5 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 2.5 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="319"/>
                    <measurement group_id="B2" value="319"/>
                    <measurement group_id="B3" value="638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Bortezomib Exposure</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Lenalidomide Exposure</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="318"/>
                    <measurement group_id="B2" value="316"/>
                    <measurement group_id="B3" value="634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Kaplan-Meier estimate of median time from randomization to progressive disease (PD) or all-cause death. PD was assessed using International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). 1 or more conditions were required to meet PD: 2 consecutive rising serum or urine M-protein from central lab; documented new bone lesion(s) or soft tissue plasmacytoma(s) or increased size of existing bone lesion(s) or plasmacytoma(s); or confirmed hypercalcemia due solely to plasma cell proliferative disorder (local lab greater than 11.5 mg/dL on 2 separate occasions). Censoring conditions (censoring dates) were: no post-baseline disease assessment (DA) (randomization date); started non-protocol systemic anticancer treatment before PD or death (last DA date before such treatment); died or had PD after more than 1 missed DA (last DA date without PD before the first missed visit); or were alive and without documentation of PD, including lost to follow-up without PD (last DA date).</description>
        <time_frame>From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.</time_frame>
        <population>ITT analysis set comprised of all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Dexamethasone (Rd)</title>
            <description>Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on Days 1 to 21 and Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22.</description>
          </group>
          <group group_id="O2">
            <title>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</title>
            <description>Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m2 was administered intravenously (IV) on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 on Days 8, 9, 15, and 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 through Cycle 12 and then from Cycle 13 through Cycle 18, 27 mg/m2 on Days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on Days 1 to 21 from Cycle 1 through Cycle 18 and from Cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22 from Cycle 1 through Cycle 18 and from Cycle 19 and higher.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Kaplan-Meier estimate of median time from randomization to progressive disease (PD) or all-cause death. PD was assessed using International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). 1 or more conditions were required to meet PD: 2 consecutive rising serum or urine M-protein from central lab; documented new bone lesion(s) or soft tissue plasmacytoma(s) or increased size of existing bone lesion(s) or plasmacytoma(s); or confirmed hypercalcemia due solely to plasma cell proliferative disorder (local lab greater than 11.5 mg/dL on 2 separate occasions). Censoring conditions (censoring dates) were: no post-baseline disease assessment (DA) (randomization date); started non-protocol systemic anticancer treatment before PD or death (last DA date before such treatment); died or had PD after more than 1 missed DA (last DA date without PD before the first missed visit); or were alive and without documentation of PD, including lost to follow-up without PD (last DA date).</description>
          <population>ITT analysis set comprised of all randomized participants</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="15.0" upper_limit="20.6"/>
                    <measurement group_id="O2" value="26.3" lower_limit="23.3" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Analysis was stratified by β2 microglobulin levels (&lt; 2.5 mg/L vs. ≥ 2.5 mg/L), prior bortezomib (no vs. yes), and prior lenalidomide (no vs. yes)</p_value_desc>
            <method>Log Rank</method>
            <method_desc>The stopping boundary for this analysis was 0.0127 based on 1-sided significance level (O’Brien-Fleming with Lan-DeMets spending function).</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.690</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.570</ci_lower_limit>
            <ci_upper_limit>0.834</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Time elapsed between the randomization date and the date of death. Participants who were still alive were censored at the date when the subject was last known to be alive or the data cutoff date, whichever occurs earlier. The median and all but one of the 95% confidence limits were not estimable. Instead, the number of participants who died or were censored are reported.</description>
        <time_frame>From randomization through the data cutoff date of 16 June 2014. Median follow up time was approximiately 32 months.</time_frame>
        <population>ITT analysis set comprised of all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Dexamethasone (Rd)</title>
            <description>Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on Days 1 to 21 and Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22.</description>
          </group>
          <group group_id="O2">
            <title>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</title>
            <description>Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m2 was administered intravenously (IV) on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 on Days 8, 9, 15, and 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 through Cycle 12 and then from Cycle 13 through Cycle 18, 27 mg/m2 on Days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on Days 1 to 21 from Cycle 1 through Cycle 18 and from Cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22 from Cycle 1 through Cycle 18 and from Cycle 19 and higher.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time elapsed between the randomization date and the date of death. Participants who were still alive were censored at the date when the subject was last known to be alive or the data cutoff date, whichever occurs earlier. The median and all but one of the 95% confidence limits were not estimable. Instead, the number of participants who died or were censored are reported.</description>
          <population>ITT analysis set comprised of all randomized participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrew Consent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0182</p_value>
            <p_value_desc>Analysis was stratified by β2 microglobulin levels (&lt; 2.5 mg/L vs. ≥ 2.5 mg/L), prior bortezomib (no vs. yes), and prior lenalidomide (no vs. yes).</p_value_desc>
            <method>Log Rank</method>
            <method_desc>The stopping boundary for this analysis was 0.0051 based on 1-sided significance level (O’Brien-Fleming with Lan-DeMets spending function).</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.787</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.628</ci_lower_limit>
            <ci_upper_limit>0.985</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response</title>
        <description>Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response based on the Independent Review Committee (IRC) assessed response outcome. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).</description>
        <time_frame>From randomization through the data cutoff date of 16 June 2014.Median follow-up time was approximately 31 months.</time_frame>
        <population>ITT analysis set comprised of all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Dexamethasone (Rd)</title>
            <description>Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on Days 1 to 21 and Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22.</description>
          </group>
          <group group_id="O2">
            <title>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</title>
            <description>Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m2 was administered intravenously (IV) on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 on Days 8, 9, 15, and 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 through Cycle 12 and then from Cycle 13 through Cycle 18, 27 mg/m2 on Days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on Days 1 to 21 from Cycle 1 through Cycle 18 and from Cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22 from Cycle 1 through Cycle 18 and from Cycle 19 and higher.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response</title>
          <description>Number of participants who achieved confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response based on the Independent Review Committee (IRC) assessed response outcome. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).</description>
          <population>ITT analysis set comprised of all randomized participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264"/>
                    <measurement group_id="O2" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control</title>
        <description>Number of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks according to International Myeloma Working Group - Uniform Response Criteria (IMWG-URC) (MR was determined using European Group for Blood and Marrow Transplantation criteria).</description>
        <time_frame>From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.</time_frame>
        <population>ITT analysis set comprised of all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Dexamethasone (Rd)</title>
            <description>Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on Days 1 to 21 and Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22.</description>
          </group>
          <group group_id="O2">
            <title>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</title>
            <description>Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m2 was administered intravenously (IV) on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 on Days 8, 9, 15, and 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 through Cycle 12 and then from Cycle 13 through Cycle 18, 27 mg/m2 on Days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on Days 1 to 21 from Cycle 1 through Cycle 18 and from Cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22 from Cycle 1 through Cycle 18 and from Cycle 19 and higher.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control</title>
          <description>Number of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks according to International Myeloma Working Group - Uniform Response Criteria (IMWG-URC) (MR was determined using European Group for Blood and Marrow Transplantation criteria).</description>
          <population>ITT analysis set comprised of all randomized participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345"/>
                    <measurement group_id="O2" value="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response (DOR) was calculated for subjects who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented Progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.</description>
        <time_frame>From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 42 months.</time_frame>
        <population>The Intent to treat (ITT) population with participantant with participants who achieved a best overall response of PR or better.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Dexamethasone (Rd)</title>
            <description>Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on Days 1 to 21 and Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22.</description>
          </group>
          <group group_id="O2">
            <title>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</title>
            <description>Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m2 was administered intravenously (IV) on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 on Days 8, 9, 15, and 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 through Cycle 12 and then from Cycle 13 through Cycle 18, 27 mg/m2 on Days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on Days 1 to 21 from Cycle 1 through Cycle 18 and from Cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22 from Cycle 1 through Cycle 18 and from Cycle 19 and higher.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response (DOR) was calculated for subjects who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented Progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.</description>
          <population>The Intent to treat (ITT) population with participantant with participants who achieved a best overall response of PR or better.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="16.7" upper_limit="25.8"/>
                    <measurement group_id="O2" value="28.6" lower_limit="24.9" upper_limit="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Disease Control</title>
        <description>Duration of disease control (DDC) was calculated for participants who achieved disease control.DDC was defined as the time in months from randomization to the earlier of documented Progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.</description>
        <time_frame>From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 46 months.</time_frame>
        <population>The Intent to treat (ITT) population with participantants who achieved disease control.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Dexamethasone (Rd)</title>
            <description>Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on Days 1 to 21 and Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22.</description>
          </group>
          <group group_id="O2">
            <title>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</title>
            <description>Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m2 was administered intravenously (IV) on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 on Days 8, 9, 15, and 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 through Cycle 12 and then from Cycle 13 through Cycle 18, 27 mg/m2 on Days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on Days 1 to 21 from Cycle 1 through Cycle 18 and from Cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22 from Cycle 1 through Cycle 18 and from Cycle 19 and higher.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Disease Control</title>
          <description>Duration of disease control (DDC) was calculated for participants who achieved disease control.DDC was defined as the time in months from randomization to the earlier of documented Progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS.</description>
          <population>The Intent to treat (ITT) population with participantants who achieved disease control.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="345"/>
                <count group_id="O2" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" lower_limit="16.6" upper_limit="22.2"/>
                    <measurement group_id="O2" value="28.7" lower_limit="24.4" upper_limit="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QLQ-C30 Global Health Status/Quality of Life Scores</title>
        <description>European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Core Module QLQ-C30 (QLQ-C30 GHS/QoL) is a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life. The minimal important difference for between group differences is 5 points.</description>
        <time_frame>Day 1 of Cycles 3, 6, 12, 18</time_frame>
        <population>ITT analysis set comprised of all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide and Dexamethasone (Rd)</title>
            <description>Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on Days 1 to 21 and Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22.</description>
          </group>
          <group group_id="O2">
            <title>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</title>
            <description>Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m2 was administered intravenously (IV) on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 on Days 8, 9, 15, and 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 through Cycle 12 and then from Cycle 13 through Cycle 18, 27 mg/m2 on Days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on Days 1 to 21 from Cycle 1 through Cycle 18 and from Cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22 from Cycle 1 through Cycle 18 and from Cycle 19 and higher.</description>
          </group>
        </group_list>
        <measure>
          <title>QLQ-C30 Global Health Status/Quality of Life Scores</title>
          <description>European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Core Module QLQ-C30 (QLQ-C30 GHS/QoL) is a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life. The minimal important difference for between group differences is 5 points.</description>
          <population>ITT analysis set comprised of all randomized participants.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
                <count group_id="O2" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 3, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread="19.4"/>
                    <measurement group_id="O2" value="59.9" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" spread="19.7"/>
                    <measurement group_id="O2" value="62.5" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" spread="19.7"/>
                    <measurement group_id="O2" value="62.7" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9" spread="18.8"/>
                    <measurement group_id="O2" value="64.3" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug until 30days after the last dose; 1-201 weeks with median of 57 weeks in Lenalidomide + Dexamethasone arm, and 1-185 weeks with median of 88 weeks in Carfilzomib + Lenalidomide + Dexamethasone arm.</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide and Dexamethasone (Rd)</title>
          <description>Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on Days 1 to 21 and Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22.</description>
        </group>
        <group group_id="E2">
          <title>Carfilzomib, Lenalidomide, and Dexamethasone (CRd)</title>
          <description>Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m2 was administered intravenously (IV) on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 on Days 8, 9, 15, and 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, and 16 of Cycle 2 through Cycle 12 and then from Cycle 13 through Cycle 18, 27 mg/m2 on Days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on Days 1 to 21 from Cycle 1 through Cycle 18 and from Cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on Days 1, 8, 15, and 22 from Cycle 1 through Cycle 18 and from Cycle 19 and higher.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="209" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="234" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Platelet disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diverticulum oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cholangitis suppurative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Genitourinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hepatic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Laryngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Listeria sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Salmonella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Testicular abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gallbladder injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Splenic injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Influenza A virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Monoclonal immunoglobulin present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Streptococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Viral test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Mineral deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fracture pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Intervertebral disc compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Leukaemia plasmacytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of pleura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cerebral cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Myxoedema coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Psychiatric decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bronchopneumopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Eosinophilic pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pleural fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute generalised exanthematous pustulosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="355" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="363" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="148" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="129" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="392"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="389"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="392"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen, Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

